9.5 Expired, Adulterated, Misbranded & Recalled Drug Products
Key Takeaways
- OAC 535:15-3-11(c) requires outdated prescription drugs to be removed from active inventory upon expiration and physically removed from the pharmacy within six months of expiration, by shipment to a reverse distributor or return to the supplier.
- A drug is adulterated when something is wrong with the product itself (contamination, unsanitary preparation, failing strength/purity/quality), and misbranded when something is wrong with its labeling or information.
- FDA recall classifications turn on the probability of harm: Class I means reasonable probability of serious adverse health consequences or death, Class II temporary or medically reversible harm, and Class III unlikely to cause adverse health consequences.
- Under the DSCSA, a dispenser must accept product only from an authorized trading partner, keep transaction information and statements for six years, quarantine and investigate suspect product, and notify FDA on Form 3911 within 24 hours of determining product is illegitimate.
9.5 Expired, Adulterated, Misbranded & Recalled Drug Products
Why this is tested: NABP Competency Statement 3.7 is a standalone sub-topic — "drug product conditions prohibiting dispensing." It sits inside the 24% Dispensing Requirements area, and it is the competency that asks: given this product in front of you, may you legally put it in a vial at all? A separate competency, 2.5.1, covers "requirements for promoting quality and safety of public health," which is where continuous quality improvement lives.
1. Expired and Outdated Stock — Oklahoma's Six-Month Rule
Most states say only that outdated drugs must be segregated. Oklahoma sets a deadline for getting them out of the building. OAC 535:15-3-11(c):
"All outdated prescription drugs shall be removed from the active inventory area upon expiration and cannot be used to fill prescriptions. The removal from the pharmacy of these expired drugs must occur within six months of expiration either by shipping to a reverse distributor for destruction or by being returned to the supplier."
Three separate obligations are packed into that sentence:
| Trigger | Required action | Timing |
|---|---|---|
| Drug reaches its expiration date | Remove from the active inventory area; may no longer be used to fill prescriptions | Upon expiration — immediately |
| Expired stock accumulating in the quarantine area | Remove from the pharmacy entirely | Within six months of expiration |
| Method of removal | Ship to a reverse distributor for destruction, or return to the supplier | — |
Exam trap. A Board inspector finds a bin of expired non-controlled tablets, correctly segregated and clearly labelled "EXPIRED — DO NOT DISPENSE," with expiration dates 14 months old. Is the pharmacy compliant? No. Correct segregation satisfies the first obligation but not the second; the six-month removal deadline is independent, and 14 months is a violation of 535:15-3-11(c).
Related storage rules a candidate should carry alongside this: OAC 535:15-3-9(h)(3) requires refrigerator and freezer temperatures to be logged twice daily (AM and PM) on days the pharmacy is open, or maintained under continuous temperature monitoring. A cold-chain excursion converts an otherwise good product into an adulterated one.
2. Adulterated vs. Misbranded — the FDCA Distinction
This pairing appears on virtually every jurisprudence exam, and the discriminator is simple once you name it: adulteration is about the product; misbranding is about the information.
| Adulterated (FDCA § 501) | Misbranded (FDCA § 502) | |
|---|---|---|
| What is wrong | The drug itself | The label, labeling, or accompanying information |
| Examples | Contains a filthy, putrid, or decomposed substance; prepared, packed, or held under unsanitary conditions; container composed of a poisonous or deleterious substance; strength, quality, or purity differs from what it purports to have; not manufactured under cGMP | Labeling is false or misleading in any particular; lacks the name and place of business of manufacturer/packer/distributor; lacks an accurate statement of quantity; lacks adequate directions for use; lacks required warnings; the required information is not prominently placed and in terms likely to be read and understood |
| Pharmacy fact patterns | A compounded preparation made in a non-compliant cleanroom; a refrigerated vaccine left out overnight; a product diluted below labeled strength | Dispensing without the required auxiliary or transfer warning; a label that omits the drug name after generic substitution; repackaging into a container without correct labeling |
Both are prohibited acts under the FDCA, and both are also independently actionable under 59 O.S. § 353.18 and the Oklahoma Pharmacy Act's prohibitions on adulteration and misbranding. Note that a pharmacist can create misbranding through a labeling error even when the manufacturer's product was perfect.
3. FDA Drug Recalls: Three Classes and the Pharmacy's Job
A recall is a firm's removal or correction of a marketed product; FDA classifies it by the probability and severity of harm:
| Class | Standard | Illustrative pharmacy example |
|---|---|---|
| Class I | Reasonable probability that use will cause serious adverse health consequences or death | Sterile injectable with particulate contamination; a product with the wrong active ingredient |
| Class II | May cause temporary or medically reversible adverse health consequences, or the probability of serious consequences is remote | Tablets slightly subpotent; a labeling error unlikely to cause serious harm |
| Class III | Not likely to cause adverse health consequences | Cosmetic container defect; a minor packaging or spelling error |
A market withdrawal is not a recall — it is a firm removing product for a minor issue that would not be subject to legal action by FDA. A medical device safety alert is a separate category.
Executing a recall in the pharmacy
- Receive the recall notice (from the manufacturer, wholesaler, FDA MedWatch, or the Board).
- Quarantine immediately — physically segregate the affected lot numbers out of active inventory so no one can dispense them.
- Search dispensing records by NDC and lot for patients who already received the product. This is why lot-level records matter.
- Notify affected patients and prescribers when the recall class and clinical risk warrant it — Class I recalls generally require patient-level notification.
- Return or destroy the product per the recalling firm's instructions, documenting quantities.
- Document the entire response and retain it for Board inspection. OAC 535:15-10-10(a) provides that any procedures or other records required to comply with Board regulations be retained for the same period as prescription records — five years — and be readily available for authorized inspection.
4. DSCSA: Suspect and Illegitimate Product
The Drug Supply Chain Security Act (Title II of the DQSA) makes a pharmacy a dispenser in a traceable supply chain. Four duties are testable:
- Authorized trading partners only. A dispenser may buy prescription drugs only from a manufacturer, repackager, wholesale distributor, or third-party logistics provider that is properly licensed or registered. In Oklahoma, wholesale distributors, repackagers, manufacturers, third-party logistics providers, and outsourcing facilities each hold their own Board license under 59 O.S. § 353.7(5). This is the legal backstop behind the Board's guidance not to borrow medications from another pharmacy without a drug supplier permit.
- Transaction records. Receive and retain transaction information (TI) and a transaction statement (TS) for each product, and keep them for six years. Note this six-year federal retention period runs longer than Oklahoma's five-year prescription record rule — the stricter standard governs each record type.
- Suspect product. On determining product may be counterfeit, diverted, stolen, intentionally adulterated, or unfit for distribution, quarantine and investigate. If the investigation clears the product, document and return it to stock.
- Illegitimate product. On determining product is illegitimate, notify FDA using Form 3911 within 24 hours, notify immediate trading partners, and work with the manufacturer to verify.
Oklahoma reinforces the paper trail at the state level: OAC 535:15-7-2(c) requires a drug supplier's sales records to include the name and address of purchaser and supplier, quantity sold, drug description, lot number and expiration date, price, and date of transaction, readily available for inspection.
5. Promoting Quality and Safety of Public Health (Competency 2.5.1)
Oklahoma places a continuous-improvement duty directly on the pharmacy and the PIC rather than framing it as optional best practice:
- OAC 535:15-3-2(c)(2): "The pharmacy and the PIC are responsible to establish and maintain effective controls against prescription errors."
- OAC 535:15-3-2(c)(4): the pharmacy, pharmacist, and PIC must establish and maintain effective controls against diversion of prescription drugs into other than legitimate medical, scientific, or industrial channels.
- OAC 535:15-3-2(f): the pharmacy, pharmacist, and PIC must implement and follow a written drug diversion detection policy, available for Board review. The Board has publicly reminded licensees that this policy — like any record required by Board regulation — must be readily retrievable and produced on inspection.
- OAC 535:15-3-2(d)(3): automated pharmacy systems must be monitored with a quality assurance program.
- OAC 535:15-3-2(c)(1): where the identity of the person who filled a prescription is not determinable, the PIC and the pharmacy are the subjects of any Board charges — a direct incentive to maintain filler-identification records.
- Separation-of-employment reporting (OAC 535:15-3-2(c)(3)): the pharmacy or PIC must notify the Board immediately by certified mail of the separation of employment of any pharmacist, intern, or technician for any suspected or confirmed drug or pharmacy-related violation. If the PIC is the one terminated, the owner or other person in charge must make the notification.
During a Board inspection of an Oklahoma retail pharmacy, the inspector finds a clearly labelled quarantine bin containing non-controlled prescription drugs that expired between 9 and 15 months ago. The drugs were removed from active stock on their expiration dates and none were dispensed. Is the pharmacy compliant with OAC 535:15-3-11(c)?
A pharmacy receives a shipment of a widely used tablet whose cartons show inconsistent lot numbering and a National Drug Code that does not match the manufacturer's published listing. The PIC concludes the product is counterfeit. What does the DSCSA require?
A manufacturer announces a recall of a sterile ophthalmic solution because of possible microbial contamination that could cause vision loss. How is this recall classified, and what does the pharmacy do first?